发明申请
US20120302572A1 USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT
有权
在癌症药物发现，诊断和治疗中使用EMT基因标志
- 专利标题： USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT
- 专利标题（中）： 在癌症药物发现，诊断和治疗中使用EMT基因标志
-
申请号： US13455972申请日： 2012-04-25
-
公开(公告)号： US20120302572A1公开(公告)日： 2012-11-29
- 发明人: Julie Kan , Stuart Thomson , Gretchen M. Argast , Matthew E. O'Connor , Murray Robinson , Bin Feng , Joerg Heyer , Maria I. Chiu , Richard Nicoletti
- 申请人： Julie Kan , Stuart Thomson , Gretchen M. Argast , Matthew E. O'Connor , Murray Robinson , Bin Feng , Joerg Heyer , Maria I. Chiu , Richard Nicoletti
- 申请人地址： US MA Cambridge US NY Farmingdale
- 专利权人： AVEO PHARMACEUTICALS, INC.,OSI Pharmaceuticals, LLC
- 当前专利权人： AVEO PHARMACEUTICALS, INC.,OSI Pharmaceuticals, LLC
- 当前专利权人地址： US MA Cambridge US NY Farmingdale
- 主分类号： A61K31/517
- IPC分类号： A61K31/517 ; A61P35/00 ; C40B30/04 ; A61K31/4985
摘要：
The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.
公开/授权文献
信息查询
IPC分类:
